Other Routine +

New Peer-Reviewed Study Reveals Actionable Immune-Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation

MediciNova’s Ibudilast Gains Brain Metastasis Validation Ahead of ALS Readout

By The Northwire Desk — AI Analysis Apr 27, 2026 · 19:00 4875

Executive Summary

Most Recent Release (April 27, 2026): MediciNova announced a peer-reviewed study published in Cancer Research demonstrating that its lead product MN-166 (ibudilast) blocks the MIF–CD74 signaling axis to suppress brain metastasis growth.
Key Findings: The study identifies tumor-derived MIF as a driver of pro-metastatic immune reprogramming in the brain and suggests secreted MIF could serve as a liquid biopsy biomarker.
Collaboration: MediciNova plans to collaborate with the Spanish National Cancer Research Centre (CNIO) on future clinical research targeting patients with solid tumors that have developed brain metastases.
Historical Context (2025-2026):
- ALS Program (COMBAT-ALS): Enrollment of 234 patients completed in September 2025. Top-line results were initially targeted for year-end 2025 (Jan 6, 2026 message) but subsequently clarified to end of 2026 (Dec 8, 2025 & Jan 29, 2026 updates).
- ALS Expanded Access: SEANOBI EAP enrolled 100 patients by January 2026 (50% of 200 target), funded by a $22 million NINDS grant.
- CIPN Program (OXTOX): Enrollment completed December 2025 in Australia; data expected late 2026.
- Metabolic Program (MN-001): Phase 2 enrollment completed November 2025; top-line data expected summer 2026. Mechanistic studies published regarding cholesterol efflux (Oct/Dec 2025).

Material Impact

Positive Validation: The publication in Cancer Research provides strong mechanistic support for MN-166 beyond its primary ALS indication, potentially expanding the Total Addressable Market (TAM) to include brain metastases from lung, breast, and melanoma.
Incremental Nature: This is preclinical/mechanistic data, not clinical efficacy data. It does not de-risk the binary outcome of the ongoing COMBAT-ALS Phase 2b/3 trial, which remains the primary value driver.
Timeline Discrepancy Risk: There is a notable inconsistency in management communication regarding the COMBAT-ALS top-line results. The January 6, 2026 CEO message targeted year-end 2025, while the December 8, 2025 enrollment update and January 29, 2026 EAP update both specify end of 2026. This suggests potential timeline slippage or optimistic forecasting in early-year communications.
Funding Stability: The reliance on a $22 million NIH grant for the SEANOBI program indicates that external funding is crucial to offset development costs, highlighting cash flow sensitivity.

4875 · Price

Company Overview

Company Profile: MediciNova is a biopharmaceutical company focused on the development of novel therapies for unmet medical needs, primarily in neurology and oncology.
Flagship Asset (MN-166/Ibudilast): A PDE4 inhibitor with anti-inflammatory properties. Currently in Phase 2b/3 for ALS (COMBAT-ALS), Phase 2 for Chemotherapy-induced Peripheral Neuropathy (CIPN), and exploring brain metastasis indications.
Secondary Asset (MN-001/Tipelukast): A leukotriene receptor antagonist/PDE inhibitor being developed for metabolic disorders including hypertriglyceridemia, NAFLD, and Type 2 Diabetes. Phase 2 enrollment completed as of late 2025.
Development Stage: Late-stage clinical development (Phase 2b/3) with multiple programs nearing data readouts in 2026.

More from